Admedus enjoys CardioCel six year celebration

THE ROADHOUSE PHARMACY: Admedus (ASX: AHZ) announced that six years post implantation CardioCel® continues to show no level of calcification or any other issues.

The company said the first patient from the Phase II study has had their six year follow up with results demonstrating there is still no detectable calcification of CardioCel® with no ‘re-do’ surgery required and no other issues.

The patient was initially implanted at three weeks of age and has now reached their sixth birthday with no implant issues.

“This is great progress for patients in not having to have additional surgeries and it represents huge potential for the future treatment of congenital heart disease and other cardiac defects,” Admedus CEO Lee Rodne said in the company’s announcement to the Australian Securities Exchange.

Admedus declared all other patients in the study have also continued to show no signs of calcification or follow up surgeries after three to five years.

The company anticipates continued data from the ongoing monitoring of these patients.

“We have always believed that CardioCel® has enormous potential in the future of cardiac surgery and this data highlights the longer term benefits of using CardioCel® and its superiority over alternatives,” Rodne said.

Patients from the Phase II study are examined for calcification and overall patient health annually.

Earlier this year Admedus received FDA clearance for CardioCel® and last year CardioCel® was approved in Europe under a CE Mark.

Email: info.au@admedus.com

Website: www.admedus.com